Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

InnoCare Approved to Start Trials of JH2 Inhibitor for Autoimmune Diseases

publication date: Mar 28, 2022

Beijing InnoCare Pharma was approved to start China clinical trials of its TYK2 JH2 allosteric inhibitor, the company’s third candidate for autoimmune disease to enter the clinic. ICP-488 binds the JH2 domain to block the signal transduction of IL-23, IL-12, type 1 IFN and other inflammatory cytokines, inhibiting the autoimmune/inflammatory process. InnoCare said the self-developed drug will be tested in patients with psoriasis and inflammatory bowel disease. In 2021, InnoCare out-licensed ex-China rights for its BTK inhibitor to Biogen in a $937 million deal, including $125 million upfront. More details....

Stock Symbols: (HK: 09969) (NSDQ: BIIB)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here